|
Philip Sager is the Chief Medical Officer of CardioDx. Prior to joining CardioDx in 2008, Philip was Executive Director at AstraZeneca Inc responsible for the medical/scientific leadership of several worldwide pharmaceutical development programs and the corporate strategies regarding QT/arrhythmia issues in drug development. From 2001-2004 he was a Director at the Schering-Plough Research Institute where he played key roles for Vytorin and Zetia. He joined the pharmaceutical industry after 11 years at the UCLA School of Medicine where he was a tenured faculty member in cardiology. Philip is Co-Chair of the Scientific Oversight Committee and Executive Committee member of the FDA-sponsored Cardiac Safety Research Consortium and is a member of the International Committee on Harmonization (ICH) E14 Expert Group. Philip graduated from MIT with degrees in Biology and Chemistry and attended Yale School of Medicine, where he also completed his medical internship, residency, cardiology, and cardiac electrophysiology fellowships. He is Board certified in Internal Medicine, Cardiology, and Cardiac Electrophysiology and has published more than 150 scientific manuscripts and abstracts. | 